Keros Therapeutics (NASDAQ:KROS) Issues Earnings Results

Keros Therapeutics (NASDAQ:KROS) announced its quarterly earnings results on Monday. The company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.25) by ($0.20), FiscalAI reports. Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%.

Keros Therapeutics Trading Up 0.4%

KROS stock opened at $10.11 on Tuesday. The firm’s 50-day moving average price is $10.68 and its two-hundred day moving average price is $12.59. Keros Therapeutics has a 12-month low of $9.69 and a 12-month high of $22.55. The stock has a market capitalization of $200.08 million, a price-to-earnings ratio of -3.36 and a beta of 0.99.

Insider Activity

In other Keros Therapeutics news, Director Nima Farzan sold 2,625 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the transaction, the director owned 9,767 shares of the company’s stock, valued at $104,799.91. This represents a 21.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.72, for a total value of $28,140.00. Following the completion of the sale, the director owned 9,767 shares of the company’s stock, valued at approximately $104,702.24. This trade represents a 21.18% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 8,425 shares of company stock valued at $89,994. Insiders own 12.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in KROS. AQR Capital Management LLC purchased a new stake in shares of Keros Therapeutics in the 1st quarter worth about $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Keros Therapeutics by 15.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock worth $227,000 after acquiring an additional 2,982 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Keros Therapeutics by 38.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock valued at $7,547,000 after purchasing an additional 205,022 shares during the last quarter. Creative Planning grew its holdings in shares of Keros Therapeutics by 40.2% during the second quarter. Creative Planning now owns 24,226 shares of the company’s stock valued at $323,000 after buying an additional 6,948 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in Keros Therapeutics by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 51,815 shares of the company’s stock valued at $692,000 after purchasing an additional 7,146 shares during the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on KROS. HC Wainwright reissued a “buy” rating on shares of Keros Therapeutics in a research note on Tuesday. Leerink Partners decreased their price objective on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a report on Tuesday. Weiss Ratings cut Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Zacks Research lowered Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 29th. Finally, Wall Street Zen lowered Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $20.83.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.